BioCentury | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

...in macular edema trial Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that THR-317...
...endpoint in a single-blind European Phase II trial in 70 patients with diabetic macular edema. THR-317...
...Vascular endothelial growth factor A Mary Romeo, Assistant Editor and Paul Bonanos, Associate Editor Acelarin (MTL-007, NUC-1031) THR-317 WP1066 Moleculin...
BioCentury | May 4, 2018
Clinical News

ThromboGenics reports Phase I/II data for DME candidate

...ThromboGenics N.V. (Euronext:THR) said THR-317 was well tolerated with no dose-limiting toxicities (DLTs) reported in the...
...4 or 8 mg THR-317 given about one month apart. In anti-VEGF treatment-naïve patients, high-dose THR-317...
...Phase II trial is evaluating THR-317 plus Lucentis ranibizumab in about 72 patients with DME. THR-317...
BioCentury | Feb 8, 2017
Clinical News

THR-317: Ph II started

...and 8 mg intravitreal THR-317 in about 50 patients. ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: THR-317...
...visit Status: Phase II started Milestone: Phase II data (1Q18) Chris Lieu ThromboGenics N.V. Placental growth factor (PGF) (PLGF) THR-317...
Items per page:
1 - 3 of 3